|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C17orf62 |
Gene summary for C17ORF62 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C17orf62 | Gene ID | 79415 |
| Gene name | cytochrome b-245 chaperone 1 | |
| Gene Alias | C17orf62 | |
| Cytomap | 17q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0002252 | UniProtAcc | A0A024R8W9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79415 | C17orf62 | P1T-E | Human | Esophagus | ESCC | 5.15e-13 | 4.91e-01 | 0.0875 |
| 79415 | C17orf62 | P2T-E | Human | Esophagus | ESCC | 3.16e-31 | 4.17e-01 | 0.1177 |
| 79415 | C17orf62 | P4T-E | Human | Esophagus | ESCC | 2.05e-08 | 2.52e-01 | 0.1323 |
| 79415 | C17orf62 | P5T-E | Human | Esophagus | ESCC | 1.25e-16 | 4.16e-01 | 0.1327 |
| 79415 | C17orf62 | P8T-E | Human | Esophagus | ESCC | 1.75e-31 | 5.83e-01 | 0.0889 |
| 79415 | C17orf62 | P9T-E | Human | Esophagus | ESCC | 2.83e-27 | 5.18e-01 | 0.1131 |
| 79415 | C17orf62 | P10T-E | Human | Esophagus | ESCC | 1.79e-20 | 3.87e-01 | 0.116 |
| 79415 | C17orf62 | P11T-E | Human | Esophagus | ESCC | 2.57e-28 | 1.19e+00 | 0.1426 |
| 79415 | C17orf62 | P12T-E | Human | Esophagus | ESCC | 3.42e-25 | 4.34e-01 | 0.1122 |
| 79415 | C17orf62 | P15T-E | Human | Esophagus | ESCC | 7.38e-32 | 6.18e-01 | 0.1149 |
| 79415 | C17orf62 | P16T-E | Human | Esophagus | ESCC | 3.90e-35 | 5.27e-01 | 0.1153 |
| 79415 | C17orf62 | P17T-E | Human | Esophagus | ESCC | 1.92e-17 | 7.06e-01 | 0.1278 |
| 79415 | C17orf62 | P19T-E | Human | Esophagus | ESCC | 8.62e-11 | 4.54e-01 | 0.1662 |
| 79415 | C17orf62 | P20T-E | Human | Esophagus | ESCC | 1.87e-20 | 2.83e-01 | 0.1124 |
| 79415 | C17orf62 | P21T-E | Human | Esophagus | ESCC | 1.49e-58 | 1.01e+00 | 0.1617 |
| 79415 | C17orf62 | P22T-E | Human | Esophagus | ESCC | 1.18e-38 | 6.60e-01 | 0.1236 |
| 79415 | C17orf62 | P23T-E | Human | Esophagus | ESCC | 3.33e-29 | 6.19e-01 | 0.108 |
| 79415 | C17orf62 | P24T-E | Human | Esophagus | ESCC | 4.67e-35 | 6.09e-01 | 0.1287 |
| 79415 | C17orf62 | P26T-E | Human | Esophagus | ESCC | 8.22e-24 | 4.55e-01 | 0.1276 |
| 79415 | C17orf62 | P27T-E | Human | Esophagus | ESCC | 1.14e-24 | 4.04e-01 | 0.1055 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C17orf62 | SNV | Missense_Mutation | c.233T>G | p.Val78Gly | p.V78G | Q9BQA9 | protein_coding | deleterious(0) | benign(0.382) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| C17orf62 | deletion | Frame_Shift_Del | novel | c.414delC | p.Thr139ArgfsTer234 | p.T139Rfs*234 | Q9BQA9 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| C17orf62 | SNV | Missense_Mutation | c.420G>C | p.Gln140His | p.Q140H | Q9BQA9 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-C5-A1ML-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| C17orf62 | SNV | Missense_Mutation | c.160G>T | p.Gly54Cys | p.G54C | Q9BQA9 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| C17orf62 | SNV | Missense_Mutation | c.319N>A | p.Val107Ile | p.V107I | Q9BQA9 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| C17orf62 | SNV | Missense_Mutation | rs768374410 | c.245C>T | p.Thr82Met | p.T82M | Q9BQA9 | protein_coding | deleterious(0.01) | probably_damaging(0.942) | TCGA-DM-A28E-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C17orf62 | SNV | Missense_Mutation | novel | c.197G>T | p.Trp66Leu | p.W66L | Q9BQA9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| C17orf62 | SNV | Missense_Mutation | novel | c.347A>C | p.Lys116Thr | p.K116T | Q9BQA9 | protein_coding | tolerated(0.29) | benign(0.015) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C17orf62 | SNV | Missense_Mutation | rs765856193 | c.419A>G | p.Gln140Arg | p.Q140R | Q9BQA9 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C17orf62 | deletion | Frame_Shift_Del | novel | c.277_278delTT | p.Phe93GlnfsTer13 | p.F93Qfs*13 | Q9BQA9 | protein_coding | TCGA-AJ-A3OJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |